Even though Inducible cAMP Early Repressor (ICER) has the functional characteristics of a tumor suppressor, there is no genetic evidence to demonstrate that ICER is a bona fide tumor suppressor gene product. Thus, altered post-translational events might be the cause of the observed abnormalities of ICER protein expression in cancer cells. On this basis it is hypothesized that in cancer cells, ICER is deregulated by ubiquitination resulting in constitutive proteasomal degradation and/or abnormal subcellular localization. Finding alternatives to rescue endogenous ICER nuclear expression in malignant cells could lead to the development of novel cancer treatment modalities. Through this project, we will study the mechanisms and physiological consequences of ICER ubiquitination and subcellular localization. We will use melanoma as a paradigm for the study. This study will focus on two specific aims.
Aim 1. Determine the functional and physiological consequences of ICER ubiquitination by characterizing the specific ubiquitination sites on ICER and ubiquitin E3 ligases using biochemistry, chromatin binding, and siRNA techniques.
Aim 2. Examine the effect on tumorgenesis upon expression of ?ubiquitinatable?-deficient ICER using mouse xenograft models and an established zebrafish model for melanoma. The overarching goal of this project is to determine the functional consequences of ICER post- translational modifications in cancer. The experiments described in this proposal will provide the basis for more extensive analyses of multi-component complexes associated with the regulation of ICER in cancer cells. Subsequent research will: 1) Use the zebrafish melanoma model to further characterize the molecular mechanisms of ICER ubiquitination during melanoma genesis; 2) Establish collaborative efforts to develop small-molecule compounds and small ICER-related peptides as specifics Ub-ligases inhibitors to test specific approaches to restore endogenous ICER nuclear expression in cancer cells; and 3) Study the effect of these Ub-ligase inhibitors in animal models for cancer.

Public Health Relevance

(Public Health Relevance Statement) This project will study how an unusual protein with tumor suppression activities in normal cells is eliminated or misplaced in cancer cells. The outcomes of this proposal will set the stage for the testing of pharmacological agents that will block the destruction and abnormal cellular localization of this protein as a potential and novel cancer treatment modality.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Enhancement Award (SC1)
Project #
1SC1GM125583-01
Application #
9415869
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Cubano, Luis Angel
Project Start
2018-05-01
Project End
2022-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Montclair State University
Department
Biology
Type
Schools of Arts and Sciences
DUNS #
053506184
City
Montclair
State
NJ
Country
United States
Zip Code
07043